CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) earnings date
Feb 17, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 39 days, typically, give or take 6 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | before open | 39 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | before open | 39 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 40 | 8-K |
| Q4 FY2025 | Wed, Feb 18, 2026 | before open | 53 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | before open | 39 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | before open | 39 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | before open | 39 | 8-K |
| Q4 FY2024 | Wed, Feb 19, 2025 | before open | 53 | 8-K |
What they guided beta
| Q3 FY2026 | "Increases 2026 guidance for revenue and non-GAAP earnings per share." exhibit |
| Q3 FY2026 | "In the third quarter of 2026, the RMS segment’s GAAP operating margin increased to 19.9% from 16.2% in the third quarter of 2025, primarily due to lower costs related to the Cell Solutions divestiture and restructuring initiatives." exhibit |
| Q3 FY2026 | "The non-GAAP operating margin decrease was primarily driven by the impact of an unfavorable revenue mix, both geographically and related to large research models. 2026 Guidance Update The Company is increasing its 2026 revenue and earnings per share guidance, which was last updated on August 5, 2026." exhibit |
| Q3 FY2026 | "On a GAAP basis, the Company is also increasing its earnings per share guidance, due primarily to the third-quarter benefit associated with the reversal of acquired tax reserves. 3 Exhibit 99.1 The Company’s 2026 guidance for revenue and earnings per share is as follows: 2026 GUIDANCE CURRENT PRIOR Revenue growth/(decrease), reported (2.0)% - (1.5)% (3.5)% - (2.5)% Less: Contribution from acquisitions 0.0% - (0.5)% 0.0% - (0.5)% Add: Impact from divestitures ~4.5% ~4.5% Less: Favorable impact of foreign exchange (0.5)% - (1.0)% (0.5)% - (1.0)% Revenue growth/(decrease), organic (1) At least +1" exhibit |
| Q2 FY2026 | "Increases 2026 guidance for revenue and non-GAAP earnings per share." exhibit |
| Q2 FY2026 | "In the second quarter of 2026, the RMS segment’s GAAP operating margin increased to 17.3% from 16.8% in the second quarter of 2025, primarily due to lower amortization of intangible assets related to the sale of the Cell Solutions business." exhibit |
| Q2 FY2026 | "As of June 27, 2026, the Company had $700.0 million remaining under its $1.0 billion stock repurchase authorization that was approved by the Board of Directors on October 29, 2025. 2026 Guidance Update The Company is increasing its 2026 revenue and non-GAAP earnings per share guidance, which was last updated on May 7, 2026." exhibit |
| Q2 FY2026 | "This increase primarily reflects the expected operational 3 outperformance for the year, including in the second quarter, due primarily to improving demand trends in the DSA segment and better-than-expected performance in the Manufacturing segment." exhibit |
| Q2 FY2026 | "The Company’s 2026 guidance for revenue and earnings per share is as follows: 2026 GUIDANCE CURRENT PRIOR Revenue growth/(decrease), reported (3.5)% - (2.5)% (5.5)% - (4.0)% Less: Contribution from acquisitions 0.0% - (0.5)% 0.0% - (0.5)% Add: Impact from divestitures ~4.5% ~5.0% Less: Favorable impact of foreign exchange (0.5)% - (1.0)% (0.5)% - (1.0)% Revenue growth/(decrease), organic (1) 0.0% - 1.0% (1.5)% - (0.5)% GAAP EPS estimate $3.05 – $3.35 $5.35 – $5.85 Acquisition-related amortization (2) ~$2.30 ~$2.30 Acquisition- and divestiture-related costs (3) ~$4.75 ~$2.30 Costs associated wi" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CRL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CRL
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CRL/"><img src="https://veritasdata.dev/embed/CRL.svg" alt="CRL earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CRL/)
Script
<script async src="https://veritasdata.dev/embed/CRL.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CRL"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.